Literature DB >> 22319220

Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma.

Stephan Ulmer1, Klara Spalek, Arya Nabavi, Susan Schultka, H Maximillian Mehdorn, Santosh Kesari, Lutz Dörner.   

Abstract

Carmustine is used in the treatment of glioblastomas as locally applied chemotherapy in the form of biodegradable wafers, which are lined on the walls of the resection cavity at the end of the resection, to increase local concentrations and decrease systemic toxicity. A total of 44 patients with glioblastoma with gross macroscopic tumor removal were included. MRIs were performed at various times postoperatively (within 24 hours, 1 week, 1 month, 2 months, 3 months, 6 months, 9 months, and 1 year). MR protocols included a T2-, diffusion-weighted, and T1-weighted sequences with and without intravenous administration of gadolinium. On T1, the wafers change from their initial hypointense to an isointense appearance after a period during which they appear to be hypointense, with a hyperintense rim most prominent less than 1 month postoperatively. On T2 they change from a hypointense to an isointense appearance. Restricted diffusivity reshaping the silhouette of the wafer's surface at the rim of the resection cavity can be found as early as day 1 postoperatively; however, 1 month after implantation, they all show areas of restricted diffusion, which may remain up to 1 year. Contrast enhancement at the rim of the resection cavity can already be found at day 1 postoperatively, with a peak shortly after 1 month after surgery. These changes can easily be mistaken for an abscess and hamper the early differentiation between residual tumor tissue and normal postoperative changes. However, early changes in either appearance do not predict overall survival or the progression free interval.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22319220      PMCID: PMC3309854          DOI: 10.1093/neuonc/nos003

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  38 in total

1.  Cost of brain tumour in Europe.

Authors:  M Ekman; M Westphal
Journal:  Eur J Neurol       Date:  2005-06       Impact factor: 6.089

2.  Space-occupying cyst development in the resection cavity of malignant gliomas following Gliadel® implantation--incidence, therapeutic strategies, and outcome.

Authors:  Lutz Dörner; Stephan Ulmer; Axel Rohr; H Maximilian Mehdorn; Arya Nabavi
Journal:  J Clin Neurosci       Date:  2011-01-14       Impact factor: 1.961

3.  Tumor bed cyst formation after BCNU wafer implantation: report of two cases.

Authors:  H H Engelhard
Journal:  Surg Neurol       Date:  2000-03

4.  Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases.

Authors:  Matthew J McGirt; Alan T Villavicencio; Ketan R Bulsara; Henry S Friedman; Allan H Friedman
Journal:  J Neurosurg       Date:  2002-05       Impact factor: 5.115

5.  The first 3 months after BCNU wafers implantation in high-grade glioma patients: clinical and radiological considerations on a clinical series.

Authors:  Alessandro Della Puppa; Marta Rossetto; Pietro Ciccarino; Giulia Del Moro; Antonino Rotilio; Renzo Manara; Marina Paola Gardiman; Luca Denaro; Domenico d'Avella; Renato Scienza
Journal:  Acta Neurochir (Wien)       Date:  2010-08-13       Impact factor: 2.216

6.  Morphological characterization of polyanhydride biodegradable implant gliadel during in vitro and in vivo erosion using scanning electron microscopy.

Authors:  W Dang; T Daviau; H Brem
Journal:  Pharm Res       Date:  1996-05       Impact factor: 4.200

Review 7.  Pseudoprogression: relevance with respect to treatment of high-grade gliomas.

Authors:  James Fink; Donald Born; Marc C Chamberlain
Journal:  Curr Treat Options Oncol       Date:  2011-09

8.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

Review 9.  Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience.

Authors:  Michael Sabel; Alf Giese
Journal:  Curr Med Res Opin       Date:  2008-10-20       Impact factor: 2.580

10.  Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma.

Authors:  S B Green; D P Byar; M D Walker; D A Pistenmaa; E Alexander; U Batzdorf; W H Brooks; W E Hunt; J Mealey; G L Odom; P Paoletti; J Ransohoff; J T Robertson; R G Selker; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  Cancer Treat Rep       Date:  1983-02
View more
  20 in total

1.  How treatment monitoring is influencing treatment decisions in glioblastomas.

Authors:  Martha R Neagu; Raymond Y Huang; David A Reardon; Patrick Y Wen
Journal:  Curr Treat Options Neurol       Date:  2015-04       Impact factor: 3.598

Review 2.  Polymeric drug delivery for the treatment of glioblastoma.

Authors:  Scott D Wait; Roshan S Prabhu; Stuart H Burri; Tyler G Atkins; Anthony L Asher
Journal:  Neuro Oncol       Date:  2015-03       Impact factor: 12.300

3.  BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial.

Authors:  Stuart H Burri; Roshan S Prabhu; Ashley L Sumrall; Wendy Brick; Brian D Blaker; Brent E Heideman; Peggy Boltes; Renee Kelly; James T Symanowski; Walter F Wiggins; Lynn Ashby; H James Norton; Kevin Judy; Anthony L Asher
Journal:  J Neurooncol       Date:  2015-05-07       Impact factor: 4.130

4.  Discriminating surgical bed cysts from bacterial brain abscesses after Carmustine wafer implantation in newly diagnosed IDH-wildtype glioblastomas.

Authors:  Alexandre Roux; Hichem Ammar; Alessandro Moiraghi; Sophie Peeters; Marwan Baroud; Gilles Zah-Bi; Joseph Benzakoun; Eduardo Parraga; Catherine Oppenheim; Chiara Benevello; Fabrice Chretien; Pascale Varlet; Frédéric Dhermain; Edouard Dezamis; Marc Zanello; Johan Pallud
Journal:  Neurosurg Rev       Date:  2021-10-14       Impact factor: 3.042

Review 5.  Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.

Authors:  P D Delgado-López; E Riñones-Mena; E M Corrales-García
Journal:  Clin Transl Oncol       Date:  2017-12-07       Impact factor: 3.405

6.  Evaluation of serial changes on computed tomography and magnetic resonance imaging after implantation of carmustine wafers in patients with malignant gliomas for differential diagnosis of tumor recurrence.

Authors:  Shiro Ohue; Shohei Kohno; Akihiro Inoue; Daisuke Yamashita; Satoshi Suehiro; Toshimoto Seno; Yoshiaki Kumon; Keiichi Kikuchi; Takanori Ohnishi
Journal:  J Neurooncol       Date:  2015-09-18       Impact factor: 4.130

Review 7.  The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.

Authors:  A Gutenberg; C B Lumenta; W E K Braunsdorf; M Sabel; H M Mehdorn; M Westphal; A Giese
Journal:  J Neurooncol       Date:  2013-03-28       Impact factor: 4.130

8.  Incomplete copolymer degradation of in situ chemotherapy.

Authors:  Pierre Bourdillon; Tanguy Boissenot; Lauriane Goldwirt; Julien Nicolas; Caroline Apra; Alexandre Carpentier
Journal:  J Mater Sci Mater Med       Date:  2018-02-17       Impact factor: 3.896

9.  Rapid regression of glioblastoma following carmustine wafer implantation: A case report.

Authors:  Junya Fukai; Hiroki Nishibayashi; Yuji Uematsu; Yonehiro Kanemura; Koji Fujita; Naoyuki Nakao
Journal:  Mol Clin Oncol       Date:  2016-05-10

Review 10.  Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.

Authors:  Raymond Y Huang; Martha R Neagu; David A Reardon; Patrick Y Wen
Journal:  Front Neurol       Date:  2015-02-23       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.